Month: May 2021

Paul Peter Tak, MD, PhD served as Professor of Medicine and Chair of the Department of Clinical Immunology and Rheumatology at the Academic Medical Centre/University of Amsterdam (AMC). At GlaxoSmithKline (GSK) he served as Senior Vice President, Chief Immunology Officer, and Global Development Leader, and oversaw the creation of a portfolio of new medicines for immune-mediated inflammatory diseases, cancer and infectious diseases. He has been CEO of Tempero Pharmaceuticals and Kintai Therapeutics, a Flagship Pioneering company, and served on the Board of multiple biotech companies.

View Article: https://apnews.com/press-release/Business%20Wire/110ab5d1a7874299b67d738c54518cec

– Advancing oncolytic viral immunotherapies that light up and destroy local tumors, while creating a durable and systemic immune response
– Phase 3 prostate cancer program enrolling patients, clinical data readouts from other ongoing clinical programs in 2021
– Company founder and former CEO Estuardo Aguilar-Cordova, M.D. inf., Ph.D., takes on role of chief scientific officer
– Nathan Caffo named chief business officer; John Canepa appointed as chief financial officer; Susan Stewart named chief regulatory officer

What if the gut, widely regarded as the body’s second brain, could offer a much more impactful means to effect broad systemic pharmacological actions of orally administered drugs based on the confluence of the enteric nervous system, immune system, and microbiome within it?

View Article: https://wxpress.wuxiapptec.com/pioneering-gut-science-kintai-therapeutics-is-bringing-a-new-small-molecule-modality-to-fruition/

First year reflections: Ten Pillars of Success for Building a Biotech Company

View Article: https://www.linkedin.com/pulse/ten-pillars-success-building-biotech-company-any-innovative-tak/